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Abstract
The paper lays out the short scientific history and characteristics of the new probiotic Lactobacillus fermentum strain
ME-3 DSM-14241, elaborated according to the regulations of WHO/FAO (2002). L. fermentum ME-3 is a unique strain
of Lactobacillus species, having at the same time the antimicrobial and physiologically effective antioxidative properties and
expressing health-promoting characteristics if consumed. Tartu University has patented this strain in Estonia (priority
June 2001, patent in 2006), Russia (patent in 2006) and the USA (patent in 2007). The paper describes the process of
the identification and molecular typing of this probiotic strain of human origin, its deposition in an international culture
collection, and its safety assessment by laboratory tests and testing on experimental animals and volunteers. It has been
established that L. fermentum strain ME-3 has double functional properties: antimicrobial activity against intestinal
pathogens and high total antioxidative activity (TAA) and total antioxidative status (TAS) of intact cells and lysates, and it
is characterized by a complete glutathione system: synthesis, uptake and redox turnover. The functional efficacy of the
antimicrobial and antioxidative probiotic has been proven by the eradication of salmonellas and the reduction of liver and
spleen granulomas in Salmonella Typhimurium-infected mice treated with the combination of ofloxacin and L. fermentum
strain ME-3. Using capsules or foodstuffs enriched with L. fermentum ME-3, different clinical study designs (including
double-blind, placebo-controlled, crossover studies) and different subjects (healthy volunteers, allergic patients and those
recovering from a stroke), it has been shown that this probiotic increased the antioxidative activity of sera and improved
the composition of the low-density lipid particles (LDL) and post-prandial lipids as well as oxidative stress status, thus
demonstrating a remarkable anti-atherogenic effect. The elaboration of the probiotic L. fermentum strain ME-3 has drawn
on wide international cooperative research and has taken more than 12 years altogether. The new ME-3 probiotic-
containing products have been successfully marketed and sold in Baltic countries and Finland.
Key words: animal experiments, antimicrobial activity, antioxidative activity, atherosclerosis, atopic dermatitis, blood lipids,
cerebral stroke, enteric infections, food supplements, functional food, glutathione, human clinical trials, intestinal microbiota,
inﬂammation, isoprostanes, lactobacilli, Lactobacillus fermentum ME-3, oxidative stress, oxidized LDL, post-prandial
lipidaemia, probiotics, probiotic patents, typhoid nodules
Introduction
The host and its microbiota together form a com-
plex ecological system. Despite temporary or some-
times even long-lasting imbalance due to various
exogenous and endogenous influences, its individual
stability is still achieved by different mechanisms.
However, the impaired composition of the micro-
biota has been associated with several health con-
sequences, which could be avoided by regulation of
the microbe and host interrelations. Probiotics
aimed at stabilizing the microbial communities and
the health-promoting effects have an important
position in the medical health care of different age
groups and diseased persons.
Diversity and functions of intestinal
microbiota
The gastrointestinal (GI) microbiota of human
beings is a dynamic and complex mixture of microbes
consisting of bacteria, archaea, protists (ciliates),
anaerobic fungi and different bacteriophages and
viruses (1). It has several diverse functions including
the decomposition of different nutrients, the matura-
tion of intestinal cells, morphology and gut physiol-
ogy, stimulation of the immune system, systemic
effects on blood lipids and inhibition of harmful
bacteria (2). The number of microbes harboured in
the human body is nearly 10 times more than the
number of somatic cells: on the skin there are 10
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microbial cells. The interrelation between the host
and its microbiota both commensals and pathogens 
is the subject of the microbial ecology of the human
organism in health and disease.
The microbial biotope produces an environment
for microorganisms with similar conditions and
volume. New microorganisms are constantly arriving
into the open system, yet they do not stay. During the
years 1960 1970, research by R. Dubos, R.W. Schae-
dler and D. Savage introduced an understanding of
indigenous microbial flora, which was composed
from autochthonous (endogenous, specific for the
host species) and allochthonous (exogenous, occa-
sional) microbes (3 5). In addition, they recognized
that two types of microbiota can be differentiated in
the cavities of particular organs: the luminal and
mucosal microbiota. In different microbial biotopes
the mucosal microbiota is composed of the auto-
chthonousmicrobesthathavebecomeresidentdueto
their adhesion to eukaryotic cells via receptors or by
harbouring in the mucin layer of mucosal mem-
branes. The species composition of mucosal micro-
biota is individually specific and stable. In contrast,
the luminal microbiota consists of some resident
unattached microbes, autochthonous microbes re-
leased from different vertical biotopes of the GI tract
and the transient allochthonous microbes from diet,
water and the environment. The latter stay in the
given biotope for a short time, then are killed or out-
competed by the resident flora. The interrelations
between luminal and mucosal microflora and its
stability in experimental animals and humans, de-
tected by earlier studies (6 9), have been confirmed
by modern molecular methods. By using denaturing
gradient gel electrophoretic analysis (DGGE), the
mucosa-associatedbacterialcommunitywasfound to
be uniformly distributed along the complete colon
(10 12). However, there are also quite different
understandings available: applying the fluorescent
situ hybridization method (FISH) using 16S rRNA-
targeted oligonucleotide probes, some authors sug-
gest that colonic microbes are not in close contact
with the mucosa and no significant differences exist
between the colonic biopsies and faecal samples (13).
The individual specificity (14,15) on one hand and
the temporal modulation of the intestinal microbiota
by different types of diet (vegetarian, western type,
etc.) and stress on the other hand complicate the
evaluation of different research results at the GI
ecosystem level (16 18). The application of novel
experimental sets (19) and sequence-based methods
for the determination of microbial diversity and their
functions, aptly called ‘the second Human Genome
Project’,willclearlyadvanceourknowledgeofhuman
microbial ecology (20 22).
Particular environmental microbes serve as an
assumption for the individually specific composition
of the indigenous microbiota of a newborn. It clearly
depends on the spectrum of the mother’s microbes,
with which the newborn gets in close contact, on the
one hand, and the individual receptor specificity/
activity of its own cells, on the other hand (14,22,23).
There is the possibility that the special genes of the
host are involved in the determination of the parti-
cularly different characteristics of microbiocenosis.
Some 20 years ago Dutch scientists showed that in
the case of Crohn’s disease in monozygotic twins, the
quantitative composition of normal faecal microflora
was genetically determined (24). Importantly, the
data showed that the pattern of antibodies directed to
the faecal bacteria of different morphotypes was
unique for each individual, thus confirming the
genetic influences of the host on their indigenous
microbiota (25,26).
Using bacteriological methods, we have postulated
that the quantitative composition of the faecal
microflora of adult monozygotic twins has the same
degree of similarity as the paired samples of a single
young healthy person (8,14). The comparison of
DGGE profiles in the faecal samples of monozygotic
twins and unrelated persons confirmed our earlier
findings on the higher similarity of the twins (22).
Monozygotic twins reveal the identity of many
genetic markers that are important for the selective
colonization of the indigenous microflora. It is well
known that both the antigenic structure of somatic
cells and their secretions, as well as the immune
reactivity, are determined by the genotype.
The composition of the intestinal microbiota
(IMB) has been determined by several endogenous
mucosal and luminal factors in the GI tract (Table I)
(1,2,27 30).
The colonization resistance (CR), defined in the
early 1970s (31), is the most important first-line
defence against invasive pathogenic organisms such
as Clostridium difficile, Salmonella, Shigella, Candida
albicans, etc. and indigenous opportunistic microbes
Table I. Main endogenous factors determining the composition
of the intestinal microbiota (IMB) (1,2,27 30).
1. Mucosal 2. Luminal
Specific pH, gases
IgA Secretion of digestive enzymes
Specificity of epithelial receptors Peristalsis
Non-specific Antagonism of microbiota
Complement Lysozyme
Lysozyme
Interferon
Mucin
Dendritic cells/Toll-like receptors
Colonization resistance
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ichia coli, Proteus sp., Pseudomonas sp. CR is a
dynamic phenomenon influenced by the host, diet
and medical interventions. Antibiotic therapy can
decrease the CR some 1000-fold (2). There are
several limitations in the protection by lactobacilli
against the development of antibiotic-associated
diarrhoea, although some association between the
counts of intestinal lactobacilli and CR against
Clostridium difficile has been found. Mainly, these
depend on the species-specific antibiotic suscept-
ibility of the individually different Lactobacillus
spp. composition and whether or not the gut
environment supports the survival of the adminis-
tered probiotic lactic acid bacteria (32).
The predominant microbial species of different
GI tract niches (oral cavity, stomach, jejunum,
ileum and colon) are not similar, depending on
the individual conditions of the biotope. However,
over the GI tract the same groups of bacteria
predominate, e.g. firmicutes, bacteroidetes, actino-
bacteria, proteobacteria, fusobacteria and the
uncultured groups (33). In the gastric cavity at
physiological acidity, the number of bacteria reaches
10
3 cfu/g, with gram-positive microbes predominat-
ing (lactobacilli and streptococci). It is well known
that the number of microbes (cfu/g) increases down
the intestinal tract, with anaerobic bacteria out-
numbering the aerobic ones by nearly a thousand
times. In the colon at different ages (10
10 11 cfu/g),
anaerobes such as Bacteroides, eubacteria, bifidobac-
teria, peptostreptococci and fusobacteria predomi-
nate over the Lactobacillus/Enterococcus spp.,
coliforms and staphylococci assessed by cultivation
on selective and non-selective media (2). The
cultivable anaerobic clostridia are exceptions, in-
cluding Clostridium perfringens and Clostridium diffi-
cile, whose counts do not exceed 10
5 6 cfu/g in
adults (2,8). New possibilities for discovering the
entity of the microbiota were achieved by the
development of experimental animal studies, as
well as studies on germ-free animals (34).
A 100 1000-fold difference has been found when
using bacteriological and molecular methods for
IMB studies; however, the crude understanding of
the predominant bacteria (bacteroids, anaerobic
cocci, eubacteria, bifidobacteria) according to the
bacteriological studies of our laboratory remains
quite similar to those obtained by molecular meth-
ods (35 40). The main difference is in some
unculturable genera like Atopobium, Clostridium
coccoides and Clostridium leptum groups, whose
relative abundance in total count is 3.1 11.9%,
23 28% and 21 25%, respectively, estimated by
the application of 16S rDNA techiques and mole-
cular genetic probes (41 43).
As regards the other groups of bacteria, the
main differences can be found in the susceptibility
to environmental factors. For example, Bifidobacter-
ium adolescentis is mainly detected by molecular
methods due to its high susceptibility to oxygen
(44) and thus can be frequently omitted in bacter-
iological studies.
Impact of IMB on host metabolism
It is well known that the microbial community of
the GI tract helps the host with the processing of
nutrients, also producing vitamins and butyrate.
The specific host microbe interactions have been
successfully studied by the estimation of different
metabolites of the host, derived by microbiota. The
concept of expression of the microflora-associated
characteristics (MACs) in a macroorganism (45)
has been further elaborated for a microbial host
crosstalk (46) having considerable value, especially
when comparing the MACs with GACs, i.e. germ-
free animal characteristics (34). Nowadays it has
been shown that the Toll-like receptors on the
different cells of the host recognize the microbiota
and form the basis for the crosstalk, which can
shape even the maturation and immunity of the GI
cells (29,47).
Nearly 20 years ago, we found a close correlation
between the counts of different groups in the IBM
and some secreted metabolic compounds (volatile
phenols of urine) in monocygotic twins (8,48).
To date, the microbial activity can be measured
using culture, labelled biomarkers, RNAs, proteins
and different metabolites. The new possibilities for
linking the microbial and host metabolic activities
evolved with the development of new molecular/
biochemical technologies (49). The genomes of
several bacteria have been sequenced, elucidating
the ecological success of different bacterial groups
in the different parts of the GI tract. For example,
Lactobacillus plantarum has been characterized by
a very large number of phosphotransferase systems
granting their success in energy accumulation, but
both bacteroidetes and some bifidobacteria had an
enormous number of genes involved in the utiliza-
tion of complex carbohydrates (50). The human
metagenome is a composite of the individual host
genes and the genes present in the genomes of the
trillions of microbes colonizing human bodies. Our
microbial genomes, i.e. microbiome, encode meta-
bolic capacities that we have not had to evolve on
our own (51). Several new methodical approaches
are in development. Transcriptional profiling (tran-
scriptomics) can be used in experimental models to
find groups of bacteria that have switched to the
expression genes involved in the utilization of
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can also be analysed using a metabolomic approach
to study the influence of drugs and diet on the
interactions between humans and the GI tract
microbiota.
Members of the 70 well-known divisions of
Bacteria (53), such as the Bacteroidetes and Firmi-
cutes, consist of more than 90% of all phylogenetic
types in humans. Their role has remained largely
unexplored; however, their balance was recently
associated with the pathophysiology of obesity in
animals and humans (54). It was shown that if
fasting-induced adipocyte factor (FiaF) expression
was repressed by microbes, the adipocytes increased
triglyceride production. Thus, the GI microbiota
also affects the energy harvest and storage (55).
Recently, we have found in elderly persons over
65 years that the intestinal Lactobacillus sp. is closely
bound to human inflammatory and metabolic
markers of blood. The count of live lactobacilli
showed a close negative correlation with an im-
portant lipid metabolism marker the oxidized LDL
(oxLDL) of blood. Moreover, colonization with L.
fermentum was negatively associated with blood
glucose level, seemingly showing its high potential
for carbohydrate metabolism (both hexoses and
pentoses) in the gut, thus limiting its absorbance
into the blood (M. Mikelsaar et al., unpublished
observations). The application of particular species
of probiotic lactobacilli seemingly could be a
challenge for health care to control the metabolic
and systemic defence reactions of the elderly,
including oxidative stress-related ones. This all
suggests the possibility to influence the host meta-
bolism by modulating the intestinal microbiota by
administering useful beneficial bacteria.
Why do we need functional food and probiotics?
The disruption of the CR-granting indigenous
microbiota, thus allowing potentially pathogenic
microorganisms to multiply, can be attributed to a
variety of illnesses. The high load of disinfectants
and antibiotics is a global problem clearly associated
with a more expressed imbalance of IMB among
large groups of populations. This leads to an
increased susceptibility to infections, and increased
inflammatory, ulcerative, degenerative and neoplas-
tic responses. Despite the wide use of antibiotics,
infectious diseases remain the major cause of death
from gastroenteritis in children, hospital infections
due to antibiotic-resistant bacteria and recurrent
infections such as urinary tract infections (E. coli),
antibiotic-associated colitis (C. difficile), persistent
peptic ulcer disease (Helicobacter pylori), etc.
In wealthy societies the increased stress of life,
the increasing number of elderly people and re-
duced physical activity are considered the reasons
for the large spread of civilization-associated chronic
diseases such as atherosclerosis, hypertonia, tu-
mours, diabetes, peptic ulcers, neurodegenerative
diseases and different syndromes such as adipositas,
fatigue and depression. The crucial role of the
impaired host functions is attributed to a wide
consumption of processed foods that are very rich
in sucrose, saturated fat and sodium. At the same
time, a lot of foods are characterized by a deficiency
of a number of human nutrients such as omega-3
fatty acids, arginine, glutamine, taurine, vitamins
and antioxidants (56).
Artificially created environments free of bacteria
contribute to the development of allergies. The
important role of the IMB, particularly lactic acid
bacteria, has been demonstrated in communities
with different degrees of industrialization. At the
beginning of the 1990s Strachan et al. (57) presented
the ‘hygiene hypothesis’ to explain the differences in
the industrialized and non-industrialized world. In
families with more siblings and living in rural areas,
there were fewer allergies than in families with just
one child and living in highly hygienic conditions;
this was explained in terms of the increased priming
of the immune system with different infections
prevalent in bigger families. However, in Australia,
Patrick Holt with co-authors (58) linked the problem
with an imbalance of IMB, which is the richest
potential immunomodulator in an infant’s organism.
IMB differences were found in young children living
in countries with different degrees of industrializa-
tion (59 61), mostly differing in hygienic conditions.
In Estonia, infants were more often colonized with
lactobacilli during the first year of life than their
Swedish counterparts (Figure 1). However, 5 years
after Estonia regained its independence from the
Soviet system, the increased income of the people
and the improvement of the food hygiene reduced
the differences in the prevalence of lactobacilli
between the Estonian and Swedish infants (62).
Moreover, prospective studies of an infant’s
colonization by indigenous microbiota in children
developing or not developing allergies showed clear
differences, expressed in the lowered colonization
resistance of allergic children (39,40,63). The
For health promotion: to compete with the
depletion of microbial variety, granting de-
fence against infection and allergies; to
compete with oxidative stress prone
changes.
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reduction of microbial variety in the environment
resulting in fewer signals to immune system. The
possibility to prevent or treat an allergy by increas-
ing the richness of microbial communities using
probiotics has attracted wide attention from
researchers and practitioners (63 65).
Probiotics   evidence-based impact on health
A probiotic is defined as a live microorganism
which when administered in adequate amounts
confers a health benefit on the host (66). Widely
accepted probiotics contain different lactic acid-
producing bacteria of human origin: bifidobacteria,
lactobacilli or enterococci. The area of commensal,
non-harmful bacteria of human origin serving as
probiotics is rapidly expanding and in 2007 more
than 3100 scientific publications were cited in the
PubMed database.
Widespread agreement in understanding the
probiotics area includes that the probiotic strains
should be safe, effective and stable in the final
product. Internationally accepted criteria have been
proposed to consider the selected microbes as
probiotics (66).
Yet, more importantly, up to now neither sufficient
nor indicative criteria for ‘probiotic status’ have been
defined. There are different in vitro and in vivo assays
for testing the functional properties and the putative
effectiveness ofcandidate probiotic strains for general
health benefits or against specified diseases, recently
revised by a project group Joint IDF/ISO Action
Team on Probiotics (67). The search for new
effective strains is an expanding process. Still, the
main problem is not due to the limited discovery of
new strains with new functional properties but in
proving their action in vivo. The mechanisms grant-
ing the survival and competitiveness of the probiotics
in different microbial ecosystems and action sites
have not been well explored. The application of
different clinical trials was the suggested clue.
The ILSI symposium (68) drafted three different
levels of probiotic action: 1) direct interactions with
gut microbiota, including pathogens, relying on
colonization resistance mechanisms; 2) fortification
of the gut barrier function by influencing the quality
of tight junctions; 3) modulation of the mucosal
immune cells amount and activity and the systemic
immune system. Thus, probiotics normalize the
composition of the intestinal microbiota and mod-
ulate the immune functions of the host. Emerging
evidence has revealed that the prevention of GI tract
colonization by a variety of pathogens is a primary
mechanism of the beneficial effects mediated by
probiotics (69 72). Besides infection control, sev-
eral gut microbes have been elaborated for use as
probiotics in functional food, which aims to prevent
and treat various other health problems such as
allergy, neoplastic growth and inflammatory bowel
diseases. There are also a few sound data about the
impact of probiotics on wide metabolic functions of
the host. The newer areas include the influence of
probiotics on the metabolism of dietary compo-
nents, like lactose digestion, lipid metabolism,
proteins and indigestible dietary compounds. To
explore the impact of different probiotics on the
cardiovascular system and lipid metabolism, impor-
tant biomarkers to blood cholesterols and triglycer-
ides, conducted only in a few well-designed clinical
studies. The important area of human physiology
that is relevant to functional food science according
to the ILSI and FUFOSE (the European Commis-
sion Concerted Action on Functional Food Science
in Europe) is, among others, the modulation of
defence against high-grade oxidative stress (56).
Nowadays the concept of functional foods, in-
cluding probiotic food and dietary supplements,
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Figure 1. Prevalence (%) of lactobacilli among Estonian and Swedish children.
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functions to improve the state of well-being and
health and reduce the risk of disease (73). The
provisional regulations of the ILSI and EU Research
Commission (FUFOSE and PASSCLAIM:
DOI.10.1007/s00394-005-1104-3) require sound
evidence of ability to either balance and enhance
the particular human functions or to reduce the risk
of certain diseases through the use of probiotic
microbes. Today, to define the health claims of a
new probiotic, primarily two independent double-
blinded, placebo-controlled studies are recom-
mended. At the same time, the application of
genomics, proteomics and metabolomics has begun
to be involved in the elucidation of the mechanisms
behind the interventions with useful bacteria (49).
Several supporting and confounding intrinsic,
ecological and technological factors may be of
importance in the selection of suitable candidates
for probiotics: properties of the strain; the metabolic
capacity of the strain during passage through the
GI tract; acid, bile and heat tolerance; and the ability
to grow in milk and to metabolize different sub-
strates, including prebiotics (32, 74 77).
The data depicted in Table II (68, 69, 78 102)
show clearly that the probiotic action, including
various health promotions, is strain specific, as
among the probiotic preparations there are repre-
sentatives of all the prevalent species of lactobacilli
and their health effects are largely variable.
Elaboration of probiotic L. fermentum ME-3 at
the University of Tartu
Short history of the scientific discovery of L. fermentum
ME-3
L. fermentum ME-3 as an antimicrobial and anti-
oxidative probiotic has been aimed at improving the
oxidative stress (OxS) status of a consumer’s organ-
ism and reducing the risk of enteral infections. The
history of the discovery of L. fermentum ME-3 began
in 1994, when joint research with Sweden started.
The University of Linko ¨ping (Prof. Bengt Bjo ¨rk-
ste ´n) initiated a scientific cooperative agreement
between the Department of Pediatrics (Dr Kaja
Julge, Dr Maire Vasar) and the Department of
Microbiology of the University of Tartu (Prof. M.
Mikelsaar) aimed at finding associations between
allergies and intestinal microbiota. The University of
Tartu had long-lasting experience in research into
microbial ecology and the lactobacilli of the human
organism (Prof. Akivo Lenzner). The faecal samples
of Russian astronauts were investigated in Tartu for
more than 20 years for detection of the composition
of lactobacilli (103,104). Prof. B. Bjo ¨rksten has
served as a visiting professor at the University of
Tartu since 1994, teaching clinical science and
advanced research principles to PhD students. For
the allergy research he chose two comparative
populations: Estonians with a low prevalence and
Table II. Evidence-based probiotic lactobacilli according to randomized double-blind placebo-controlled studies (adapted from 68,69).
Strain affiliation Licensing enterprise Published clinical evidence (reference no.)
Lactobacillus acidophilus
La5
Chr. Hansen, Denmark Suppression of Helicobacter pylori infection (78)
L. acidophilus L1 Campina Melkunie, Holland Blood cholesterol-lowering effect (79)
Lactobacillus johnsonii LA1 Nestle, Switzerland Suppression of Helicobacter pylori colonization in children (80)
Lactobacillus gasseri OLI
27168
Meij Milk Products, Tokyo, Japan Suppression of Helicobacter pylori infection (81)
Lactobacillus casei Shirota Yakult, Japan Reduction of constipation, reduced proteolytic activity of IMB (82,83)
L. casei DN114001 Danone, France Reduction of winter infections in elderly (84), diarrhea and respiratory
infections in adults (85,86).
Lactobacillus paracasei
LP-33
Un-President Enterprise Corp.,
Tainan, Taiwan
Reduction of allergic rhinitis (87)
Lactobacillus rhamnosus GG
ATCC 53103
Valio, Finland Reduction of diarrhoeal infections and allergy (88 92); increased
expression of immune response genes (93)
L. rhamnosus GR-1 and L.
reuteri RC-14
Chr. Hansen, Denmark Reduction of diarrhoeal infections in children (94)
L. rhamnosus HN001 Danisco, Denmark Enhanced immunity of consumers (95)
Lactobacillus plantarum
299V
Probi, Sweden Reduction of infectious complications in transplantation patients;
decrease of intestinal permeability (96)
Lactobacillus brevis CD2 VSL Pharmaceuticals, Inc., Fort
Lauderdale, FL, USA
Reduction of Helicobacter pylori infection, reduction of levels of
polyamines in gastric mucosa (97)
Lactobacillus reuteri ATCC
55730
BioGaia, Sweden Reduction of diarrhoeal infections, enhancement of consumers’ im-
munity (98,99)
Lactobacillus fermentum
ME-3 DSM 14241
AS Tere, Estonia Anti-atherogenic effect due to increase of antioxidative activity indices,
decrease of GSSG/GSH ratio and oxLDL of sera (100 102)
IMB, intestinal microbiota; GSSG/GSH ratio, glutathione redox ratio; oxLDL, oxidized low-density lipoprotein.
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Wellcome Trust supported the study.
In this period more than 200 Lactobacillus strains
of different species were collected (38,105). These
strains have formed the basis of the culture collec-
tion of the Department of Microbiology, which is
financed according to a national programme of
collections in Estonia. On 2 March 1995, five L.
fermentum isolates were obtained from a 1-year-old
Estonian child (A.M., nr. 822). Paediatricians had
previously confirmed the good health of the child,
and it continues to be excellent at the age of 12
years. The microbiological work was performed by
researchers Epp Sepp (MD, PhD), Paul Naaber
(MD, PhD), Krista Lo ˜ivukene (MD, PhD), Mall
Tu ¨ri (Pharm. cand. med.), and senior research
technician Eha-Mai Laanes. However, in this arena
there could be no invention registered, as the strains
of the L. fermentum species were also found from
some other Estonian children, yet not from Swedes!
In 1996 the Dutch company MONA offered the
University of Tartu an opportunity to test their
collection of L. acidophilus strains for antioxidativite
properties. The Dutch people relied on the research
of Japanese authors (106) who had found, with
non-standardized methods, some single antioxida-
tive lactobacilli strains among hundreds tested. We
were introduced to MONA by docent Seppo Salmi-
nen of the University of Helsinki, our research
partner in the first stages of the introduction of the
probiotic Lactobacillus GG in Finland. In turn, we
invited into the research the scientists from the
Department of Biochemistry (Prof. Mihkel Zilmer)
who had published the first interesting papers on
the markers of cellular oxidative stress (107 109).
Great efforts were made to get the antioxidative
markers run with bacterial cultures, as the disruption
of microbial cells without any enzymatic influence
was complicated and quite different from the pre-
vious work of biochemists studying the antioxidativ-
ity by methods originally developed in blood and
blood cells. It was quite hard to achieve the cell-
free extracts with no growth, as some intact cells
of lactobacilli were always found after disruption.
Then we switched to the supernatant of the dis-
rupted lactobacilli cells, comparing this with the
response of intact cells.
The cooperative work between the microbiolo-
gists and biochemists succeeded in obtaining
adequate samples; however, to great disappoint-
ment, no strains with good antioxidative properties
were found from the Dutch MONA collection. In
contrast, among the included lactobacilli of the
Estonian and Swedish children from our own
culture collection, the biochemist Tiiu Kullisaar
found two promising L. fermentum strains (strains
822-1-1 and 822-1-4, used in the laboratory under
the acronyms E-3 and E-18).
Now there was a growing hope for invention!
The protocols for new research projects were
developed with the participation of several other
microbiologists (Heidi Annuk, Reet Ma ¨ndar, Jelena
S ˇts ˇepetova and Epp Songisepp) and biochemists
(Kersti Zilmer, Tiiu Vihalemm, Ceslava Kairane
and Ann Kilk).
Then, suddenly, we made a substantial mistake:
an abstract on the two promising antioxidative
lactobacilli strains was presented in Kiel to the
congress of the International Dairy Federation.
The materials of this congress were published and
this paper excluded the novelty of the strains for our
patent application (110). Thus, the priority was
shifted for the use of the antioxidative properties in
the probiotic preparations of the strains. We had to
go further with only one strain to develop an
innovative probiotic with tested functional proper-
ties, that was safe for consumption and effective in
animal and human trials. This work has been
performed in close association with clinicians of
the University of Tartu and research partners from
Finland and Italy. The European Research Council
5th FW offered the possibility of a joint volunteer
study by the application of the synbiotic preparation
(including our antioxidative strain of L. fermentum)
with scientists of Reading University, UK (Prof.
Glen Gibson); Wageningen University, The Nether-
lands (Prof. Willem de Vos); Lund University,
Sweden (Prof. Go ¨ran Molin) and Turku University,
Finland (Prof. Seppo Salminen). The results are
presented below.
Development of the probiotic L. fermentum ME-3
The development of the probiotic started according
to provisional rules (73), later to some extent
comprising the regulations of the FAO/WHO (66).
According to WHO/FAO experts, it is necessary to
properly check the strain’s systematic, i.e. its identi-
fication by phenotypic and genotypic methods,
and deposit it in an international culture collection.
At this stage the suitable acronym ME-3 was also
developed and the strain was deposited in an
international culture collection (Deutsche Samm-
lung fu ¨r Mikroorganismen und Zellkulturen,
DSMZ 14241).
The origin, habitat and species of the Lactobacillus
strains have a great impact on their value as
probiotics. L. fermentum is a normal inhabitant of
the human intestinal tract in the UK (111) and Italy
(112). Some L. fermentum strains are able to
metabolize cholesterol (113). There seems to be
an age-dependent colonization by L. fermentum.I n
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below the age of 3 years and the number of positive
samples only increased with aging, reaching 72%
in the elderly (114).
In 1995, the prevalence of L. fermentum in
the Estonian group of investigated 1-year-old
children (105) was also low (11%), whereas in
adults and the elderly it reached 55 70% (14).
The low prevalence of L. fermentum as a species in
young children was indirectly confirmed with an
immunoblot study of 25 healthy children (A-L.
Prangli et al., unpublished observations). The differ-
ent protein domains of the three tested species of
indigenous lactobacilli (L. acidophilus, L. fermentum
and L. plantarum) induced the production of IgG
antibodies with differing prevalence in the sera of
control children. IgG antibodies directed to
L. fermentum ME-3 showed a lower number of
immunoreactive protein MW regions (kDa) than to
L.plantarum,whosespecies hasbeenmorefrequently
detected (33% vs 11%) than the former among the
microflora in children (105). This finding correlates
well with the results of previous studies showing that
different Lactobacillus spp. could possess different
immune system activating properties (26,115,116)
that may also be related to their colonization ability in
different people.
It is well known that the main microbes of the
normal microbiota of a child are obtained during
labour from the mother’s vagina and perineum, and
from skin, breast milk and the maternity hospital
environment. L. fermentum is a frequent inhabitant
of the vagina (14). The successive colonization with
a mainly gram-positive microbiota is speeded up
if the child is breast-fed and in close contact with its
mother (36). Afterwards, with the introduction of
solid food the microbiota becomes more diverse.
However, up to the second year of life an infant’s
microbiota is still different from an adult’sa s
regards some groups of bacteria and their metabolic
activities; yet it starts to more closely resemble the
adult’s microbiota (117). Seemingly, the maturation
of the host immune and receptor systems and
differences in consumed food are responsible for
the usual discovery of L. fermentum in adults and
not in young children. Thus, a child originally
harbouring the ME-3 strain could be considered
an exceptional one.
Proper identification
The probiotic strain ME-3 was identified according
to its morphological (Figure 2) (41, 118, 119) and
cultural properties, negative catalase test, produces
lysozyme, gas from glucose and NH3 from arginine,
and the acidity in milk is relatively low (1.07%).
According to the API 50 CHL kit (BioMerieux,
France) analysed by API Lab Plus softwear, very
good identification rates were obtained (ID 99.6%,
T 0.87, only one test against). The strain is able to
ferment ribose, galactose, D-glucose, D-fructose,
D-mannose, aesculin, maltose, lactose, melibiose,
saccharose, D-raffinose, D-tagatose and gluconate
(118, 120).
The internal transcribed spacer polymerase chain
reaction (ITS-PCR) followed by enzymatic restric-
tion was used to confirm the species identification of
the strain as Lactobacillus fermentum (105, 118).
According to the changes in the previous taxonomy,
the II biotype of L. fermentum has now been given
distinct species status   L. reuteri with type strain
DSM 20016, isolated from humans showing
the close relationship of these two species (69,99).
Further, in the patenting process in the US, it was
necessary to prove the difference between ME-3 and
the L. reuteri strain RC-5 (previously assessed as L.
fermentum RC-5 (69)). We used ITS-PCR followed
by restriction by the Taq I enzyme and compared
the restriction banding pattern with the reference
Figure 2. Lactobacillus fermentum ME-3 (DSM 14241) (118,
119). (a) Light microscopy, Gram stain, magniﬁcation 1000.
(b) Fluorescent in situ hybridization (FISH). Probe: Lab 158,
Lactobacilli enterococci according to Franks et al. (41).
8 M. Mikelsaar & M. Zilmerstrains of L. fermentum ATCC 14931 and L. reuteri
DSM20016) (S ˇts ˇepetova, laboratory protocol).
Further, the fingerprints of strain ME-3 (by
arbitrarily primed PCR (AP-PCR) with two primers
ERIC1 and ERIC2, DNA Technology A/S, Aarhus,
Denmark) were compared with some other L.
fermentum strains (Figure 3), important in recogniz-
ing the strain in different materials such as faeces
and functional food (119 121).
In the Dutch laboratory of Wageningen Univer-
sity (Professor Willem de Vos), the EU Marie Curie
stipend Jelena S ˇts ˇepetova succeeded in showing the
position of strain ME-3 in the phylogenetic tree of
Lactobacillus spp. (Figure 4) by sequencing the 16S
rRNA of strain ME-3, cloning it into the Escherichia
coli strain, sequencing using the Sanger method and
constructing the phylogenetic tree (J. S ˇts ˇepetova,
unpublished observations).
Metabolic activity
According to the systematics developed by Kandler
and Weiss (122), the strain ME-3 belongs to the
obligately heterofermentative lactobacilli with a char-
acteristic type of metabolism. We have determined
the metabolites of Lactobacillus sp. by the gas
chromatographic method using the Hewlett-Packard
model 6890 of gas chromatography (Figure 5) (123).
The metabolism (Table III) was dependent on the
environment, whereas in an anaerobic environment
as compared to a microaerobic one, much more
ethanol and succinic acids were produced (121).
Recently we have discovered that strain ME-3 is
able to produce nitric oxide (NO) in MRS medium
(Table III). NO production was assessed by the
Apollo free radical analyzer 400 in MRS fluid
media (Oxoid, UK) after incubation for 48 h. The
NO is able to induce among others the protection
against inflammation, while in an ischaemic heart
the NO can functionally activate the cellular anti-
oxidant defence systems (124).
In the decarboxylation medium (125) containing
amino acids such as arginine, ornithine, lysine and
histidine, it was possible to assess the production of
the polyamine putrescine and minimal amounts of
biogenic amine cadaverine (B1 ml/ml) by ME-3.
This amount is really minimal compared with
E. coli, which produced significantly larger amounts
of cadaverine (240 ml/ml) in the lysine media.
The metabolism of the putrescine is closely
connected with organic acids metabolism, as in
gut putrescine may be converted into the acetylated
and oxidated succinate. Besides, it is known that
some polyamines can serve as antioxidants (126).
When strain ME-3 was grown in milk media for
4, 10, 20, 30 and 40 days, no biogenic amines were
detected, confirming the safety of strain ME-3 for
the production of functional food (123).
Acid and bile tolerance
The definition of probiotic implies that the bacteria
should be viable at the time of ingestion and after
passage through the GI tract. This should be
achieved by the ability of a particular probiotic strain
to tolerate the highly acidic conditions present in the
stomach and the concentrations of intestinal juices
and bile salts found in the small intestine. Several in
vitro assays, including tolerance to the harsh condi-
tions of the digestive tract and adhesion to the host’s
gut epithelial cells, have been used to demonstrate
the survival of the probiotic strain inside the gut
(127). Usually after oral administration the expected
results include faecal recovery of the strain and
correction of the imbalance of intestinal microflora
by the probiotic (128, 129). However, it has not been
assessed if the improvement of the microbial balance
in the upper part of the digestive tract should always
ME-3 1 3 2 3 4 5 ME-3M100bp 2
Figure 3. AP-PCR ﬁngerprints for different L. fermentum strains. The two lanes of strain ME-3 have been generated using two DNA
samples that were extracted with a time interval of 6 months. Lanes 2 and 3 contain DNA of L. fermentum strains isolated from the same
person. Lane M contains a 100 bp DNA ladder.
Antimicrobial and antioxidative probiotic 9be expressed in the abundant microbial communities
of the large intestine and faecal samples. In experi-
mental animal studies, it has been shown that there
was quite a few association ( B30%) between the
mucosal flora of the upper parts of the gastrointest-
inal tract and the fecal microflora (23, 35). Pereira
and Gibson (113) have thoroughly studied the degree
of acid and bile tolerance of the human isolate
Figure 4. Phylogenetic tree based on 16S rRNA sequencing showing the relationship of L. fermentum ME-3 to the closest related
lactobacilli. Analysis was performed with the ARB software package.
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Figure 5. Gas chromatography of polyamines of L. fermentum ME-3 in the decarboxylation medium with ornithine (123).
10 M. Mikelsaar & M. ZilmerL. fermentum KC and have shown its ability to
maintain viability for 2 h at pH 2 and to grow in a
medium with 4 mg of bile acids per litre.
L. fermentum ME-3 was found to tolerate the
drop of pH values from 4.0 to 2.5 without a loss in
viable cell count. Even at pH 2.0 the strain survived
for 6 h and only after that the numbers of viable
cells fell rapidly (118). Strain ME-3 tolerated all the
tested bile concentrations (0.3 2.0%) similarly well
during 24 h without any remarkable loss in viable
counts. By the co-action of pH and pepsin followed
by bile and pancreatin, a decrease of 0.5 log to 1.5
log of viable count was noticed. Also, the producer
of strain ME-3 freeze-dried culture (Probiotical OY,
Novara, Italy) has confirmed the tolerance of strain
ME-3 to harsh environmental conditions. Besides,
the high stress tolerance of strain ME-3 in harsh GI
tract conditions after a 3-week consumption of goat
milk fermented by the addition of strain ME-3 was
shown (Figure 6) by confirmation of strain ME-3 in
faecal samples of 100% of volunteers by molecular
methods (101).
Lectin typing
The carbohydrate pattern of ME-3 cell surfaces
was tested with different lectins in the laboratory
of Professor Torkel Wadstro ¨m (University of
Lund, Sweden). Lectins are oligomeric and multi-
meric plant or animal proteins or glycoproteins
with binding specificities toward a particular carbo-
hydrate structure. Multimeric structure gives
lectins the ability to agglutinate cells or form
precipitates with glycoconjugates (130). The mono-
saccharides such as N-acetylglucosamine, N-
acetylgalactosamine and mannose are present in
the glycocalyx of lactobacilli in significant amounts
in the typical gram-positive envelope (131). These
sugars have been linked to adhesive properties of
lactobacilli. L. fermentum ME-3 whole cells, similar
to other tested lactobacilli strains of the same
species, showed specificity to D-Gal, D-GalNAc
carbohydrates by lectin Bandeirarea simplifolica I
(132). Harbouring this profile seemingly helps
Table III. Production of short chain fatty acids (SCFAs),
ethanol, polyamines, conjugated linoleic acid (CLA) and
nitric oxide (NO) by L. fermentum ME-3 DSM 14241 in
comparison with Lactobacillus plantarum DSM 21380.
Indices* ME-3 DSM
21380
1
Short chain fatty acids
(mg/ml) 24 48 h
incubation
Lactic acid 10.6 11.1 10.1 11.6
Acetic acid 0.8 0.9 0.08 0.1
Succinic acid 1.8 1.9 0.07 0.07
Ethanol 9.8 7.5 0
Polyamines (mg/ml)
96 h incubation
Decarboxylation of
arginine
Putrescine 0 0
Cadaverine 0.6 0
Decarboxylation of
glutamine
Putrescine 0.8 0
Cadaverine 0.5 0
Decarboxylation of
ornithine
Putrescine 1.3 0.5
Cadaverine 0 0.6
Conjugated linoleic acid
(mg/l)
12.4 39.9
NO production (mM) 1.290.2 2.690.8
H2O2 production (mM) 4849200 1969129
*Microaerobic environment.
Figure 6. Recovery of L. fermentum ME-3 in faecal samples of all volunteers after consumption of ME-3 fermented goat’s milk.
Antimicrobial and antioxidative probiotic 11strain ME-3 to compete with E. coli for adhesion to
gal-gal receptors in the intestinal tract, where E. coli
some virulent strains can be reservoir for recurrent
urinary tract infection.
We have seen some effect in a clinical trial for
preventing this recurrent infection in children. The
data in the literature showed that re-infection with a
new uropathogenic E. coli residing in the intestinal
tract occurred in nearly 75% of adult women (133).
We wondered if colonization with strain ME-3 could
suppress the potentially pathogenic E. coli and de-
crease the recurrent episodes. In vitro experiments
were promising, as the E. coli ATCC strains and
several clinical isolates were suppressed on culture
media for 2 3 log cfu/g. We hoped that this could
decrease the load of uropathogenic E. coli in the
intestinal tract to prevent new recurrent episodes of
urinary tract infections. Children who had experi-
enced a first attack of acute pyelonephritis consumed
either strain ME-3 or a placebo for 3 months: in the
placebo group, the recurrence rate was 50% while in
the strain ME-3 group it was a somewhat lower 32%
(Vainuma ¨e, dissertation in preparation).
Antimicrobial activity
The prevention of GI tract colonization by a
variety of pathogens is a primary mechanism of
beneficial effects mediated by probiotics (70,71).
It has been shown that the large spectrum of
different metabolites is responsible for the suppres-
sion of the growth of pathogens in vitro and for their
competitive exclusion in animal models. Many of the
metabolites produced by lactic acid bacteria have a
broad antimicrobial activity against some other
species, especially gram-negative ones, in contrast
to particular bacteriocins that usually inhibit only
closely related species among other gram-positive
bacteria (134).
L. fermentum ME-3 has the ability to suppress
mainly gram-negative bacteria but to some extent
also enterococci and Staphylococcus aureus. Its antag-
onistic properties against enteral pathogens (Salmo-
nella Typhimurium and Shigella sonnei), and urinary
tract infections caused by E. coli, were assessed
by a streak line procedure on plates containing
modified (pH 7.2) MRS medium (135 137). In
different environmental conditions (microaerobic
and anaerobic milieus) the production of lactic
acid by strain ME-3 correlated well with its antag-
onistic activity.
Beside lactic acid, the acetic and succinic acids
and ethanol produced in substantial amounts by
strain ME-3 in microaerobic conditions, the produc-
tion of NO and H2O2 could be responsible for the
antimicrobial effect (Table III). In her PhD disserta-
tion, Heidi Annuk was able to construct a diagram
showing that the in vitro antagonistic activity, see-
mingly due to a pH drop and organic acids produc-
tion, was quite characteristic of particular
fermentative groups of lactobacilli (homo-, faculta-
tively heterofermentative and obligately heterofer-
mentative) further identified by ITS-PCR (137).
Recently, we have found by the ROS analyser
(APOLLO 4000) that the ratio of signals H2O2:NO
was 13.7, produced by strain ME-3 in MRS
medium, achieving the first rank among about 30
tested strains of Lactobacillus species. This shows
that strain ME-3 is able to manage with both
compounds to suppress antagonists and/or initiate
signalling using several pathways (Table III).
Remarkably, the modest antimicrobial activity
of L. fermentum ME-3 (138) expressing some
antimicrobial cationic peptides against the Helico-
bacter pylori reference strain NCTC 11637 was
changed for high activity against clinical H. pylori
isolates (139). So far, the most effective manage-
ment of H. pylori infection causing gastritis and
peptic ulcer disease is combined antimicrobial
therapy. Some authors have applied the antagonistic
effect of lactic acid bacteria against H. pylori
in the prevention of and therapy for H. pylori
infection (140), although some failures are also
described.
Seemingly, a different tropism of the pathogen
and probiotic, besides the inadequacy of the dosage
and intervention, survival of the probiotic in
the gut and Lactobacillus spp. differences in antag-
onistic activity and immunomodulating properties,
could emerge among putative reasons for the low
efficacy of probiotic therapy in GI infections (141).
Moreover, the main mechanisms of probiotic
action such as competing for nutrients, producing
antimicrobial substances, blocking the adhesion and
toxin receptor sites, removing it by co-aggregation,
stimulating the immunity, increasing the barrier
function and the attenuation of virulence have to
be differentially expressed in extra- and intracellular
infections, and in fact, they are rarely all present
in a particular probiotic.
Thus, strain ME-3 possesses several antimicrobial
characteristics such as acetic, lactic and succinic
acids, putrescine, NO, CO2 and H2O2, produces
some cationic peptides, has a suitable lectin profile
for competitive adhesion to the epithelium and
some immunogenic properties, as assessed in animal
experiments and human studies.
Safety
First, lactobacilli and bifidobacteria are histori-
cally considered safe for their close association
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normal indigenous microbiota and their pathogenic
potential is low. However, some Lactobacillus spp.
strains have been associated with systemic and
local infections (142). They can cause a problem
in a world with an increased immunocompromised
population. Laboratory investigations, experimental
animal studies and volunteer trials were conducted
to test the safety of the ME-3 strain. The in vitro
experiments confirmed the absence of haemolysins
and the suppression of indigenous lactobacilli and
bifidobacteria, tested in co-cultivation experiments
with particular strains.
The most important feature for safety assurance
suggested by a large EU study was the absence
of transmissible antibiotic resistance genes/plasmids
and the natural resistance to trimethoprim plus
sulfamethoxazole, metronidazole, fluoroquinolones
and cefoxitin that corresponded to the wild strains
of the L. fermentum species (143).
The safety of ME-3 has been tested repeatedly in
a mouse model (NIH line conventional male mice,
Kuopio Finland) administered commercial diet
R-70 (Lactamin, Sweden). The experiments were
performed according to European Convention
regulations for animal experiments no. 123 from
1986. Freeze-dried L. fermentum ME-3 was added
to the tap water in a daily dose of 9.7 log cfu for
30 days. The mice were monitored and the faeces
were collected individually for the detection of
strain ME-3 daily. All strain ME-3-challenged
animals remained in a good state during the feeding
trial. Furthermore, safety was also confirmed
by feeding mice during several months with a
probiotic ME-3 cheese in different doses (136).
The mice were killed by cervical dislocation
and autopsies were performed under sterile condi-
tions using a Class II microbiological safety cabinet
(Jouan, France). To estimate the content of lactic
acid bacteria in the terminal ileum and colon,
bacteriological investigations were carried out im-
mediately. No translocation of the probiotic strain
into any organs (ileum, liver and spleen) was
detected. The increase (from 8.690.3 before to
9.190.2 log cfu/g after the trial, p 0.003) in total
faecal lactic acid bacterial counts was observed only
at the end of the 30-day experiment (Truusalu,
dissertation in preparation).
Antioxidative effects
Survey of oxidative stress and antioxidative effects
Oxidation is essential to living organisms for
energy production. However, it is now well estab-
lished that abnormal formation of the reactive
species (including free radicals) occurs in vivo and
can lead to the damage of lipids, proteins, nucleic
acids and carbohydrates of cells and tissues (144).
In the human body reactive oxygen species (ROS)
and reactive nitrogen species (RNS) are the main
players. Both terms involve appropriate free radicals
and non-radical species A free radical is defined as
an atom or molecule having at least one unpaired
electron in its outer orbital; examples include
oxygen-centred radicals (superoxide radical, hydrox-
yl radical), nitrogen-centred radicals (nitric oxide,
nitric dioxide radical), sulphur-centred (RS
- thiyl),
and some others. Principal ROS are superoxide
radical, hydroxyl radical, lipid peroxyl radical and
non-radical hydrogen peroxide (the latter is pro-
duced from superoxide by superoxide dismutase).
Principal RNS are nitric oxide and non-radical
peroxynitrite. The pathological efficiency of the
hydroxyl radical is the most potent and it is rapidly
generated via the Fenton cycle where free iron (a
very potent prooxidant) reacts with hydrogen perox-
ide (144).
ROS and RNS are generated within the body
from different external reactions (radiation, pollu-
tants, toxins, chemicals and drugs) and internal
univalent biochemical redox reactions. Several dis-
eases are associated with the toxic effect of the
transition metals (iron, copper and cadmium).
An excessive production of reactive species leads to
an imbalance in the prooxidants antioxidants sys-
tem. Any imbalance in favour of the prooxidants
potentially leading to damage was termed ‘oxidative
stress’ (145).
There is a large body of evidence that high
grade oxidative stress (OxS) has one of the crucial
roles in the pathogenesis of several disorders/dis-
eases of the GI tract (inflammatory bowel disease,
coeliac disease, etc.), the vascular system (athero-
sclerosis, myocardial infarction, stroke, vascular
dysfunctionality), the nervous system (Alzheimer’s
disease, Parkinson’s disease), the liver (ethanol
damage, cirrhosis), the skin (several dermatoses),
the pancreas (diabetes mellitus) and the eyes
(age-related macular degeneration, retinopathy)
(144 152). Metabolic syndrome, obesity, premature
ageing and the development of several tumours also
have an OxS-related background (153).
Atherosclerosis is characterized by many potential
risk markers such as increased values of
low-density lipoprotein (LDL)-cholesterol and ele-
vated blood pressure, while HDL-cholesterol, fasting
triacylglycerol and plasma homocysteine are sug-
gested as the diet-related markers (154). Moreover,
the increased inflammatory markers (white blood
cells (WBCs), highly sensitive C-reactive protein
(hsCRP)) and the oxidative stress indices (oxidized
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be characteristic of patients with atherosclerotic
lesions of the vascular system, having developed
cardiovascular disease (CVD) (146).
For the systemic multi-level control of OxS, the
human body has evolved an integrated antioxidant
defence system (Figure 7). It includes both the non-
enzymatic antioxidants like reduced glutathione
(GSH) and vitamins E, C and Q10, blood albumin,
uric acid, bilirubin and enzymatic antioxidants like
superoxide dismutase (Cu, Zn-SOD, Mn-SOD),
glutathione peroxidase (GSHPx), catalase (CAT)
and haem oxygenase (144).
Several antioxidative components that are inte-
grated into the human antioxidant defence system
are derived from foodstuffs and/or provided
by GI microbiota. However, up to the mid-
1990s a few studies (106) had been carried out to
screen for the antioxidative properties of indi-
genous microbiota, including bifidobacteria and
lactobacilli. Furthermore, it became apparent that
the integrated antioxidant defence system and GI
microbiota of the human body are very tightly
linked, whereas specific strains with physiologically
effective antioxidative properties may have a great
impact on the management of the OxS level in the
gut lumen, inside mucosa cells and in the blood, to
support the functionality of the integrated antiox-
idant defence system of the human body.
Some new trends for medical bioremedia-
tion target the application of microbial catabolic
diversity against aging and several major age-related
diseases such as atherosclerosis. This follows
the historical hypothesis of Metschnikof sugges-
ting the intensive consumption of lactic acid bacteria
in order to postpone aging (cited in Vaughan
et al. (155)). However, it was not assessed whether
the increased content of lactobacilli and temporal
colonization with their particular strains could influ-
ence the inflammatory and OxS-derived blood
indices. We have tried to explore this gap in our
probiotic studies.
Studies on the antioxidative effect of
L. fermentum ME-3
In vitro studies
In 1996 we started to check the antioxidative
characteristics of a large number of Lactobacillus
spp. strains. Applying a number of different tests
we found that two strains of L. fermentum may
have an impact as new probiotics with functional
properties towards antimicrobial and antioxidative
action. Both strains (E-3 and E-18) and their
lysates had physiologically relevant multivalent
antioxidativity (TAS and TAA test) to overcome
the exogenous and endogeneous OxS of the
host (156). The antioxidative properties of L.
fermentum ME-3 and demonstrated effects are sum-
marized in Table IV (100 102, 136, 156 164, 167).
Researcher Ann Kilk of the Department
of Biochemistry performed PCR for the detection
of manganese superoxide dismutase (Mn-SOD) in
ME-3 cells. Mn-SOD is very important in the
control of lipid peroxidation. Manganese and
Mn-SOD activity of lactobacilli (not having a usual
catalase) is important for their survival in the
Oxidative stressors
(Pro-oxidants)   
Antioxidative defence
system  
Ischaemia/reperfusion 
Inflammation 
Smoking 
Xenobiotics 
PUFA megadoses 
Iron and copper excess 
Radiation, Exhaustive 
exercise, Prolonged 
severe emotional stress 
Vitamin E, C, Q etc. 
Enzymatic antioxidants 
(SOD, GSHPx, CAT, HO1) 
Other antioxidants 
(GSH, plasma albumin, 
uric acid, bilirubin, 
carotenoids, etc.) 
LDL
OxLDL
Oxidative stress
ME-3
Inflammation
CVD, etc.
a.
b.
Figure 7. A net of prooxidants and the potency of antioxidant
defence system normally balanced in the human body. (a) A
summary effect of oxidative stressors and potency of antioxidant
defence system of the human body are normally balanced. An
imbalance leads to oxidative stress. PUFA, polyunsaturated fatty
acids; SOD, superoxide dismutase; GSHPx, glutathione perox-
idase; CAT, catalase; HO1, haem oxygenase; GSH, reduced
glutathione. (b) Oxidative stress causes the production of oxidized
LDL (oxLDL), which is a potent atherogenic and inﬂammatory
agent. Strain ME-3 lowers the level of oxLDL. LDL, low-density
lipoprotein; CVD, cardiovascular diseases.
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tion of H2O2 (165, 166).
Furthermore, researcher Tiiu Kullisaar designed
an original set of experiments showing that strain
ME-3 (its previous in-laboratory acronym was E-3)
had a good hydroxyl radical scavenging efficiency
and was able to survive in high concentrations of
hydrogen peroxide content and superoxide anions
quite similarly to a highly ROS-resistant Salmonella
Typhimurium, although lactobacilli did not have a
catalase as compared with salmonellas (156). The
survival in the presence of different ROS was
possible due to GSH that is a major non-enzymatic
intracellular antioxidant and protector-molecule
(144). Recently it was established that ME-3 cells
possess a complete glutathione system for its synth-
esis, uptake and redox turnover (158).
An independent laboratory confirmed that the in
vitro superoxide anion scavenging efficiency of strain
ME-3 was more than 80 100 times stronger as
compared with trolox or ascorbic acid (Ahotupa,
personal communication). That the antioxidant
properties of strain ME-3 prevented the oxidative
spoilage of soft cheese products has also recently
been confirmed by experiments in Finland (159).
Experimental animal infections
Next, an animal model of typhoid fever was
developed by the inoculation of mice with Salmo-
nella Typhimurium (161). S. Typhimurium induces
generalized infection in mice with typhoid nodules
(granulomas) in the liver and spleen.
In the prophylactic and treatment model with an
S. Typhimurium challenging of mice, the applica-
tion of L. fermentum ME-3 was not able to eradicate
salmonellas from organs, yet strain ME-3 sup-
pressed the excessive OxS-related reactions caused
by the infectious agent and the inflammation. The
enhanced lipid peroxidation and the abnormal
glutathione redox ratio were corrected and thus
the gut mucosal antioxidative status was improved
(161).
The still wide prevalence of typhoid fever in
southern countries and the treatment problems
have got our attention. Therefore, we have applied
the same experimental typhoid fever model for
the elaboration of the treatment principles of S.
Typhimurium infection with an antimicrobial
quinolone (ofloxacin) combined with the probiotic
ME-3. The combinations of antimicrobial prepara-
tions with probiotics have been used with good
success for the treatment of H. pylori infections, yet
mainly to cope with adverse effects (140). We
succeeded in showing the priority of the combination
for the eradication of salmonellas from the intestinal
tract and liver (Figure 8) and also the reduction
of typhoid nodules (granulomas) in the liver
(Figure 9).
Meanwhile, the indices of lipid peroxidation
were reduced (Table V) and the glutathione redox
ratio (GSSG/GSH) was significantly lower in
Table IV. Antioxidativity-related properties and effects of strain
ME-3.
Property/effect Experimental (ES), animal (AS),
human (HS) study (reference nos)
Expression of Mn-SOD,
prolonged survival time in
presence of high H2O2,
scavenging of superoxide
and hydroxyl radicals
ES (156)
Characterized by high TAA
and TAS values
ES (156,157)
Containing of GSH and
related antioxidative
enzymes
ES (157,158)
Working as natural antioxi-
dant in soft cheese spreads
with different fats
ES (159)
Maintaining its high TAA
during production of
probiotic cheese
ES (136)
Removal effect of metals
(prooxidants) from
environment
ES (160)
Elevation of blood TAS or
TAA and TAA in the gut
mucosa
HS, AS (100,102,157,161,162)
Elevation of oxyresistance of
LDL
HS (100,157,162)
Lowering level of oxLDL HS (100,102,162)
Lowering level of
isoprostanes
HS (100,162,163)
Lowering the glutathione
redox ratio in blood, in the
gut mucosa, in skin
HS, AS (100,102,157,161,164)
Lowering lipid peroxidation
in the gut mucosa
AS (161,164)
Lowering level of BCD-LDL HS (100,162,167)
Positive effects on post-
prandial status of OxS,
blood lipoprotein status
and urine isoprostanes
HS (162,163)
BCD-LDL, baseline diene conjugates in low-density lipoprotein;
GSH, reduced glutathione; H2O2, hydrogen peroxide; LDL,
low-density lipoprotein; Mn-SOD, manganese superoxide dis-
mutase; oxLDL, oxidized low-density lipoprotein; OxS, oxida-
tive stress; TAA, total antioxidative activity; TAS, total
antioxidative status.
Antimicrobial and antioxidative probiotic 15mice treated with the combination of strain
ME-3 and ofloxacin (164).
Our last in vivo experiments on the NIH
mouse model showed that the administration
of strain ME-3 induces high levels of anti-inflamma-
tory cytokine interleukin (IL)-10 in both the gut
and liver tissue. This could be the reason for the
reduced number of typhoid nodules in the liver in
mice treated with a combination of ofloxacin and
strain ME-3 (164).
Thus, strain ME-3 helps to alleviate OxS-
and inflammation-related disorders in the intestinal
cells in different ways (cf. discussion about ME-3
action mechanisms).
Volunteers and clinical trials
Strain ME-3 colonization and safety, as well as its
antioxidative effects, have been tested in several open
placebo-controlled and randomized double-blind
placebo-controlled clinical trials (100 102,162,167)
using capsules with ME-3, goat milk fermented with
ME-3, commercial foodstuffs (kefir, cheese) and
synbiotics enriched with ME-3. A large spectrum of
indices measured in healthy adult volunteers showed
that the use of strain ME-3 was safe regarding the
physiological values of blood cytokines (including
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Figure 8. The number of mice with viable Salmonella Typhimurium in ileum, blood and liver. Gr1, Salmonella Typhimurium (ST)-
challenged mice; Gr2, ST treated with oﬂoxacin (OFX); Gr3, ST treated with strain ME-3; Gr4, ST treated with OFX  strain ME-3.
1p 
0.032 Gr1 vs Gr2 ST in ileum;
2p 0.002 Gr1 vs Gr3 and Gr4 ST in ileum;
3p 0.002 Gr1 vs Gr3 and Gr4 ST in liver.
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Figure 9. The number of mice with typhoid nodules in liver and spleen.
4p 0.027 Gr1 vs Gr3;
5pB0.001 Gr1 vs Gr4;
6p 0.023 Gr2 vs
Gr4;
7p 0.002 Gr1 vs Gr2 and Gr4;
8p 0.048 Gr2 vs Gr3 and Gr3 vs Gr4.
Table V. Indices of oxidative stress (with standard deviations) in
the ileum mucosa in mice challenged with S. Typhimurium and
treated with oﬂoxacin and/or the probiotic L. fermentum ME-3.
Experimental groups LPO (pmol/mg
protein)
GSSG/GSH
Salmonella Typhimurium chal-
lenged mice (Gr1)
338946
1;4 0.2690.41
3;5
ST treated with ofloxacin
(OFX) (Gr2)
228941
2 0.2690.11
ST treated with strain ME-3
(Gr3)
169911
1;2 0.1690.20
3
ST treated with OFX   strain
ME-3 (Gr4)
161927
1;2 0.1790.11
3
Control (PBS) 157924
4 0.1190.2
5
GSSG/GSH, glutathione redox ratio; LPO, lipid peroxides; OFX,
ofloxacin; PBS, phosphate-buffered saline; ST, Salmonella
Typhimurium.
1pB0.001 Gr1 vs Gr3 and Gr4;
2p 0.002
Gr2 vs Gr3 and Gr 4;
3p 0.006 Gr1 vs Gr3 and Gr4;
4pB0.001 Gr1 vs control;
5pB0.003 Gr1 vs control.
16 M. Mikelsaar & M. ZilmerIL-6), inflammatory markers (WBCs, hsCRP), prin-
cipal markers of carbohydrates and lipids or lipid-
like compounds (glycose, triglycerides, cholesterol,
LDL, HDL), several metabolites (homocysteine,
creatinine, bilirubin) and several other biochemical
indices such as blood calcium and iron, and en-
dothelial functionality and arterial stiffness.
The consumption of strain ME-3 had a positive
influence on the gut microbiota. The faecal counts of
beneficial lactobacilli were increased in several
studies (Figure 10) offering protection against colo-
nization by potential pathogens if the volunteers
consumed goat milk fermented by strain ME-3
(daily dose 3 10
11 cfu) or used freeze-dried capsu-
lated ME-3 (10
9 cfu per capsule twice a day) as well
for 3 weeks. In contrast, in the group of volunteers
consuming non-fermented goat milk, a decrease in
total lactobacilli counts was seen during the 3-week
trial. However, a significant difference was found
concerning the applied formulations. In the goat
milk trial strain ME-3 was molecularly (ITS-PCR)
assessed in all volunteer consumers, yet strain ME-3
was not detectable among ME-3 isolates by bacter-
iological methods or by AP-PCR in the probiotic
capsule trial, although there was a positive shift in
blood indices. In capsulate forms higher quantities of
bacteria (up to 10
10 cfu/g) have been suggested to re-
isolate the probiotic bacteria from faecal samples
(168,169).
At the same time, the consumption of ME-3
bacteria-containing substances showed positive
effects on several OxS-related indices such as post-
prandial lipid, lipoprotein and OxS profile of blood
and urine (162). Consumption of kefir containing
strain ME-3 significantly decreased the post-
prandial content of fats, oxLDL and BDC-LDL,
enhanced the level of HDL and improved the
bioquality of HDL particles.
Synbiotic trial. L. fermentum ME-3 was also applied
in the EU Research Commission-funded project
‘EU and Microfunction Functional assessment of
interactions between human microbiota and host’
(QLRT-2001-00135; ISRCTN43435738) using a
randomized, double-blind crossover synbiotic inter-
vention study with 53 healthy volunteers (167,170).
The composition of the synbiotic was as follows:
probiotics L. fermentum ME-3, L. paracasei 8700:2,
Bifidobacterium longum 46 (both Probi, Sweden) and
5 g of prebiotic Raftilose P95 (Orafti, Belgium).
Several shifts in the microbiota composition were
assessed by research partners at Reading University
(UK), such as an increase in bifidobacteria and
clostridia counts, associated with appropriate shifts
in profiles of faecal metabolites (short chain fatty
acids, SCFAs). An increase in the total antioxidative
activity was also registered (Table VI) accompanied
by an improved bioquality of LDL particles
(oxLDL and BDC-LDL) of sera of volunteers after
consumption of the symbiotic for 3 weeks.
However, half of the healthy asymptomatic
volunteers in this trial were colonized with H. pylori.
All applied probiotic strains expressed a high
antagonistic activity against the H. pylori reference
strain in vitro (138). Despite the consumption of the
symbiotic for 3 weeks, this composition could not
eradicate the H. pylori infection (167). Seemingly
the application of the entero-coated probiotic cap-
sules prevented the direct effect of lactobacilli on H.
pylori on gastric mucosa. Thus, the antagonistic
bacteria, including strain ME-3, were not able to
exert any systemic antimicrobial influence on H.
pylori colonization, although the same consumed
composition improved the antioxidative indices of
blood in persons colonized with H. pylori.
Special clinical trials on patients. On the basis of the
information about safety and the positive effects
of strain ME-3 in healthy volunteers, we also
conducted some preliminary clinical pilot trials.
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Figure 10. Increase of total faecal counts of lactobacilli in healthy
volunteers consuming strain ME-3 in fermented goat milk and in
the DBRP probiotic capsule efﬁcacy trial (118).
*pB0.005 difference from pretreatment values; %pB0.01 differ-
ence between ME-3 and control treatments.
Table VI. Improvement of OxS-related indices of blood sera in
the synbiotic DBRP crossover study in healthy volunteers (167).
Blood indices Baseline Final
synbiotic
Paired t test
TAA% 41924 2 92 B0.001
oxLDL (ApoB-
modified)
132.5950.5 122.8945.6 0.047
BDC-LDL (diene
conjugates)
15.296.1 12.794.1 B0.001
BCD-LDL, baseline diene conjugates in low-density lipoprotein;
oxLDL, oxidized low-density lipoprotein; TAA, total antiox-
idant activity.
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patients with mild to moderate atopic dermatitis
consumed goat milk fermented with strain ME-3
for 3 months (102). The clinical SCORAD index
decreased from 4.893.9 to 1.991.8 (pB0.05) in
the probiotic group and from 4.892.8 to 2.390.9
in the control group. A significant amount of
oxidized iron (prooxidant) was found in the skin
of patients before consumption and the values of
iron were decreased. Also, the diene conjugate
values (indicating lipid peroxidation) were reduced
(Figure 11). In the same group, the antioxidativity
markers of blood also showed an improvement.
The levels of oxLDL decreased, and GSH
(a protective form of glutathione) levels increased
with a concomitant reduction in the GSSG/GSH
ratio both in the skin and in the blood level. The
results of our study demonstrated that the regular
use of probiotics with antioxidative properties
decreased inflammation and concomitant OxS
in adult patients with mild to moderate atopic
dermatitis (102,162).
The second DBRP pilot trial (162) was aimed at
evaluation of the antioxidative effect of strain ME-3
on a seriously ill group of patients who had survived
a stroke. The 21 patients (80.499.9 years), who
had survived a brain stroke 1296.6 days earlier,
were randomly distributed into two groups. In
addition to regular rehabilitation therapy that in-
cluded ACE inhibitors, aspirin, diuretics and beta-
blockers, the patients were assigned to consume for
3 weeks, twice a day, either capsules (3 per
capsule 10
9 cfu) of freeze-dried ME-3 (ME-3
group, 10 subjects) or placebo capsules (3 250
mg saccharose and microcellulose, control group,
11 subjects), respectively. The functional ability of
the stroke patients was assessed before
and after the 3-week treatment period using two
clinical evaluation scales (Table VII). The Func-
tional Independence Measure, FIM, assesses 18
activities of self-care, mobility, locomotion, commu-
nication and social cognition on a 7-point scale
from fully independent to fully dependent. The
Scandinavian Stroke Scale, SSS, is more specific
to stroke patients and measures nine items: level of
consciousness, mobility of eye, upper and lower
limb, orientation, speech, facial tone and gait. The
biochemical indices of sera were evaluated twice:
before and after treatment (162). The baseline
values of the ME-3 and control group were not
statistically different. After rehabilitation and the
course and consumption of the antioxidative pro-
biotic, only the ME-3 group showed improved
biochemical indices (GSSG, oxLDL, diene conju-
gates (DC), TAA) and the correlation between
improved OxS-related indices and the functional
ability scales (between SSS and oxLDL, r  0.55,
pB0.05) and FIM (between FIM and GSSG/GSH,
r  0.63, pB0.03). However, in the placebo
group the FIM values got even better than in the
ME-3 group, seemingly due to the lower starting
level of the patients in the ME-3 group. In addition,
the application of ME-3 capsules caused a signifi-
cant decline in the values of inflammatory markers
(hsCRP) not assessed in the control group.
Figure 12 illustrates the effects of strain ME-3 for
increasing the oxiresistance of LDL particles and
lowering the level of oxLDL.
Thus, this pilot trial shows the potential of strain
ME-3 to be applied as an adjunct preparation to the
ordinary rehabilitation therapy of patients in the
course of recovering from a brain stroke.
Possible mechanisms of effects of
L. fermentum ME-3
In different experiments and volunteer and clinical
trials, the administration of strain ME-3 has led to
the improvement of the GI microbial ecology. More
than a 10-fold increase of total lactobacilli counts in
Figure 11. Content of iron and diene conjugates in the skin in patients with atopic dermatitis (AD), regularly (3 months) consuming
probiotic strain ME-3. *pB0.05 comparing the values before and after consumption.
18 M. Mikelsaar & M. Zilmercomparison with the individually different initial
count was registered in the collected faecal samples,
regardless of the probiotic formulation or daily dose
applied. It was supposed that the metabolites
secreted by strain ME-3 into the GI tract could be
used as a substrate by other lactobacilli. The
tolerance to different environmental factors and
the successful passage of strain ME-3 through the
GI tract has also been confirmed by culture and
PCR-based methods (100,101).
At the same time, by adding L. fermentum
strain ME-3 as a probiotic ingredient into a dairy
product (yoghurt, cheese, milk), it was able to
suppress the putative contaminants of food such
as pathogenic Salmonella spp., Shigella spp., urinary
tract infections caused by E. coli, Staphylococcus spp.
The amounts of secreted SCFAs, the substantial
amount of hydrogen peroxide (120,138,156) and
production of NO by strain ME-3 were seemingly
the main antimicrobial operators. The method for
the simultaneous suppression of pathogens and the
enhancement of the antioxidative activity of food
was filed in a US patent application (171). Thus,
the double functional properties of the probiotic
strain L. fermentum ME-3 may protect the host
against food-derived infections on one hand and
help in the prevention of oxidative damage of food
on the other hand. The intact cells and cell-free
extract of strain ME-3 showed different potent
antioxidative effects due to the expression of the
antioxidant enzymes such as Mn-SOD and the
components of the complete glutathione system
(GSH, glutathione peroxidase and glutathione re-
ductase). The antioxidative protection offered by
strain ME-3 for the prevention of oxidative spoilage
of semi-soft cheeses was assessed in an independent
study in Finland (159).
Furthermore, we have looked for the implemen-
tation of the functional properties of strain ME-3 to
improve antimicrobial defence and some metabolic
functions in different hosts.
Experimental animal studies (161,164) have
confirmed that the increase in total lactobacilli
counts as much as the specific strain ME-3
antioxidative action in the gut eradicated live
salmonellas and prevented the formation of typhoid
nodules in experimental Salmonella Typhimurium
infections, resembling typhoid fever in humans. For
the first time it was shown that the antibiotic
therapy of an invasive infection like enteric fever
was more effective if administered together with
a probiotic. However, it cannot be excluded that
beside the antimicrobial and antioxidative effect
of strain ME-3, immune enhancement by the
probiotic also played a significant role.
Figure 12. Increase of oxiresistance of low-density lipoprotein
(LDL) particles (minutes) and lowering oxidized-LDL level
(absorbance units) after using strain ME-3. Oxidation of LDL is
measured on the basis of conjugated dienes at 234 nm.
Table VII. Clinical and biochemical evaluations of stroke patients: parameters at the baseline (before) and after an application period (after)
by means of SSS and FIM scale and biochemical indices (mean9SED) (162).
Parameter ME-3 group Placebo group
Clinical parameter Before After Before After
SSS 33913 42912
2 37912 4599
1
FIM 21919 40923
3 32916 50916,
1,4
Biochemical indices
LDL-cholesterol (mmol/L) 3.992.2 3.891.9 3.290.8 3.291.1
4
oxLDL (U/L) 121935 109935
1 130923 128922
4
DC (mmol/L) 50994 5 98
3 45916 45914
GSSG (mmol/L) 64916 52918
2 73928 71918
4
GSSG/GSH 0.0790.01 0.0590.01
1 0.0790.02 0.0690.01
TAA (%) 34914 6 93
2 37913 5 941
4
DC, diene conjugates; FIM, Functional Independence Measure; GSSG, oxidized glutathione; GSSG/GSH, glutathione redox ratio;
LDL, low-density lipoprotein; oxLDL, oxidized low-density lipoprotein; SSS, Scandinavian Stroke Scale; TAA, total antioxidant activity.
1pB0.05,
2pB0.01 and
3pB0.001 as compared to baseline value;
4pB0.05 as compared to the ‘After’ values in the ME-3 and placebo
groups.
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tive properties of strain ME-3 in humans, we have
developed a method for enhancing the antioxidative
activity of sera, i.e. administering strain ME-3 in a
food product to humans comprising increases in
TAA, TAS, and the lag phase of LDL and decreases
in oxidized glutathione, oxLDL and BCD-LDL of
sera (171). Different trials have shown that the
application of strain ME-3 alleviates inflammation-
and OxS-related shifts in gut, skin and blood (100 
102,162). This is based on complicated cross-talk
between strain ME-3 and host cells with the
integrated influence of several factors such as the
ability of strain ME-3 to apply a complete glu-
tathione system, the expression of antioxidative
enzymes in strain ME-3, the production of CLA
and NO by strain ME-3, etc.
The question was raised as to how it was possible
to exert a positive effect such as the reduction of
OxS just by consuming a food product? Strain
ME-3 of human origin was successful in surviving
different fermentation processes of milk due to its
good tolerance to low temperature, acid and salt
(118,136), and was capable of the temporal coloni-
zation of the intestinal tract of the consumer.
The intestinal surface is an important host
organism environment boundary and the interac-
tions of gut microbes inside the intestinal lumen and
mucosal cells are important for the host, as was
shown in the characterization of the composition and
metabolic acitivities of intestinal microbiota in the
first sections of the review. An impaired environment
such as the imbalance of GI microbiota, but also the
increase of lipid peroxidation and decrease of the
reduced GSH both at the intestinal surface and in
the intestinal cells, are the mighty modulators
causing different unhealthy outcomes in the host.
That these modulators of the intestinal mucosal
status can be repaired by the administration of strain
ME-3 was directly confirmed in a mouse model of
experimental S. Typhimurium infection (161,164).
In this process the involvement of the glutathione
system is crucial as GSH, besides its role as a crucial
antioxidant, is the principal redox controller for a
number of processes in cells. Glutathione-related
information has impact for strain ME-3 regarding at
least two aspects: a) a recent adapted conception of
OxS is advanced as ‘a disruption of redox signalling
and control’ (145,172) that emphasizes an impact of
GSH and its redox ratio as good tools for the
quantification of OxS and the signalling role of
GSH, described also by us (173,174); and b) there
exists the possibility for the effective participation of
strain ME-3 in both enzymatic and non-enzymatic
glutathione-driven protection. Besides, the data that
just L. fermentum as a species significantly counter-
acted the depletion of colonic glutathione content
induced by some inflammatory processes (175) also
supported our understanding. In addition, there
exists a correlation between glutathione redox ratio
and DNA oxidative damages (176).
Further, our research has shown that the
improvement of the intestinal extra- and intracellu-
lar environment yielded beneficial changes of some
general/systemic biochemical indices of the host.
This was proven by the administration of strain
ME-3 to healthy volunteers and atopic adults
leading to a reduction of lipid peroxidation and a
counterbalance of the glutathione system both in
blood and in skin. Moreover, in several conducted
trials we have seen the positive effect of strain ME-3
on the blood LDL fraction: the prolongation of its
resistance to oxidation, the lowering of the content
of oxLDL (potent inflammatory and atherogenic
factor) and BDC-LDL and the enhancement of the
total antioxidative capacity of sera (100,101,167).
In our recent investigation of elderly persons over
65 years, the lower content of oxLDL was signifi-
cantly predicted by the higher count of live lacto-
bacilli in the GI tract (M. Mikelsaar et al.,
unpublished observations). Seemingly, both the
particular antioxidative characteristics of strain
ME-3 and the increase in lactobacilli counts in-
duced by its administration could be responsible for
the registered impact on the host lipid metabolism.
The status of OxS and blood lipoprotein are both
related to the development of different diseases,
including inflammation-related diseases and CVD
(see above). Recently in Circulation (177) the
pathophysiological continuum that traditional cardi-
ovascular risk factors all promote OxS and endothe-
lial dysfunction   the first steps in a cascade of
pathological events   was highlighted. OxS leads to
the overproduction of oxLDL and the latter has a
great impact on the development of atherosclerosis.
For example, the higher levels of circulating oxLDL
are strongly (much more than LDL-cholesterol)
associated with an increased incidence of metabolic
syndrome already in people who are currently young
and healthy according to a large population-based
study (178). It was previously shown that oxLDL
is an important determinant of structural changes
of the arteries already in asymptomatic persons (147,
179). Recent data gathered from the literature
suggest that the increased production of atherogenic
and inflammatory oxLDL within the vessel wall
suppresses several immunity-related cells, including
regulatory T cells (180) exerting antiatherogenic and
antiallergic effects. In addition, it is widely accepted
that post-prandial abnormal events are crucial as
regards the development of CVD (181).
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OxS indices has also been assessed by the decline of
the values of isoprostanes and 8-OHdG in urine
(100,101,162). Both indices are accepted as very
informative markers for human systemic OxS
burden (144,145). Evidently the systemic antiox-
idative effect of strain ME-3 starts from the
alleviation of the OxS- and inflammation-related
abnormalities in the intestinal cells that lead to the
assembling of particles of chylomicrons, LDL and
HDL with a higher bioquality with lower levels of
harmful oxidation products and higher concentra-
tions of antioxidant enzymes in their particles.
Furthermore, the increased bioquality of assembled
lipoprotein particles is bound to aid the improve-
ment of their metabolism/circulation in the host
body. This is one of the possible explanations why
strain ME-3 exerted the prolonged resistance of
the blood lipoprotein fraction to oxidation, lowered
the level of oxLDL and enhanced the total anti-
oxidative capacity of sera in both healthy and
diseased strain ME-3 consumers (100,101,162,
163). Our recent data have shown that administra-
tion of strain ME-3 alleviates the post-prandial
elevation of triglyceride levels in the blood, and
improves HDL bioquality (elevation of antioxidative
enzyme level in HDL particles) (162,163). This
new HDL-related antioxidative information is sup-
ported both by our findings of anti-inflammatory
effects of strain ME-3 on the liver (164) and by
a hepato-protective role for paraoxonase against
inflammation, fibrosis and liver disease mediated
by OxS (182).
The necessity for new approaches in global
cardiovascular risk reduction has become widely
accepted (183). In the prevention of cardiovascular
risk the anti-inflammatory agents and antioxidants
are considered as a possible ‘third great wave’
(184). The prevention complexes of several diseases
could become more successful by also including
probiotics with multivalent biopotency. Hopefully
the antimicrobial and antioxidative probiotic
L. fermentum ME-3 has earned its place in this
putative list of health promoters.
Summary and conclusions
The probiotics aimed at stabilizing the microbial
communities and the health-promoting effects have
an important position in the medical health
care of different age groups and diseased persons.
This paper describes the process of the discovery,
identification and molecular typing of the strain of
human origin, Lactobacillus fermentum ME-3 (DSM-
14241), elaborated according to the regulations
of WHO/FAO (2002). In this review the authors
have attempted to compile the available information
concerning the ability of L. fermentum ME-3 to
protect the host from different diseases induced by
pathogenic bacteria (Salmonella spp., Shigella spp.
and urinary tract infections cause by E. coli),
inflammation and oxidative stress.
Safety and health-promoting studies of the
probiotic strain cited in this report were carried
out by assessing a large number of microbiological,
biochemical and clinical indices. This strain is still
unique among Lactobacillus species, having both
antimicrobial and physiologically effective antioxi-
dative properties. Tartu University has patented this
probiotic strain in Estonia (priority June 2001,
patent in 2006), Europe (pending), Russia (patent
in 2006) and USA (patent in 2007).
The functional efficacy of this multipotential
probiotic has been proven by the eradication of
pathogenic microbes and the reduction of liver and
spleen granulomas in Salmonella Typhimurium-
infected mice treated by the combination of oflox-
acin and L. fermentum strain ME-3. When used in
capsules or foodstuffs (yoghurt, kefir, cheese) L.
fermentum ME-3 expresses several health-promoting
effects. It has been shown in different subjects
(healthy volunteers, patients) with different clinical
study designs (including double-blind, placebo-
controlled, crossover studies) that this probiotic
increased the counts of lactobacilli in the intestinal
tract, lowered the 8-isoprostanes content in urine,
increased the antioxidative activity, lowered the
content of atherogenic oxLDL, and improved
post-prandial lipid as well as oxidative stress status
in sera, thus demonstrating an anti-atherogenic
effect.
The elaboration of the probiotic L. fermentum
strain ME-3 has drawn on wide international
cooperative research and has taken more than
12 years altogether. The new probiotic products
containing strain ME-3 have been successfully
marketed and sold in Baltic countries and Finland.
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